How long does Methoxphenidine last?

The total duration of Methoxphenidine via oral is 6 hours to 8 hours. Onset typically occurs within 30 minutes to 1 hour.

Methoxphenidine — SubstanceWiki

Q: What is Methoxphenidine?

Chemical compound Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the

Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral potency. Of the three isomeric anisyl-substituents methoxphenidine has affinity for the NMDA receptor that is higher than 4-MeO-diphenidine but lower than 3-MeO-diphenidine, a structure–activity relationship shared by the arylcyclohexylamines.

Harm Reduction

How It Feels

The onset is slow, measured, and offers little warning of the depth that follows. Forty-five minutes pass with only a subtle heaviness in the limbs and a faint dulling of ambient sound. You might adjust your position on the sofa and notice that the act of moving feels slightly more deliberate than usual, as though your body is responding on a quarter-second delay. An hour in, and the dissociation is unmistakably present but still gathering force, building with the slow inevitability of a weather front moving across a plain.

The come-up continues to deepen well past the first hour, and confusion arrives alongside the dissociation like an uninvited twin. This is Methoxphenidine's defining quality: a cognitive opacity that thickens as the experience deepens, making thought itself feel labored and uncertain. You begin a sentence and find the end of it has wandered off somewhere. You look at a familiar object and know that you should recognize it but cannot quite locate the word or the meaning. Sound is muffled and strange, as though arriving from a great distance and through an unfamiliar medium. The body is numb and heavy, pinned to whatever surface you are lying on by a gravity that seems to have doubled.

At the peak, the confusion becomes the experience. You are not observing interesting dissociative phenomena from a point of detached clarity — you are simply confused, deeply and thoroughly, in a way that affects every level of cognition. Spatial reasoning collapses; the room may seem to have rearranged itself, or to extend in directions that should not exist. Time is profoundly disrupted — you have no idea whether five minutes or two hours have passed, and the question itself seems difficult to formulate. Closed-eye space is dark and disorganized: fragmented images, half-formed scenes that collapse on inspection. There is no euphoria to speak of, though the numbness itself is not unpleasant.

The duration is punishing — eight to twelve hours, with the confusion persisting long after the dissociation has begun to lift. The return to baseline is slow and marked by a heavy, hung-over feeling: thick-headed, slightly dizzy, and fundamentally tired. Memory of the experience is patchy at best; entire hours may be simply missing. Sleep, when it finally arrives, is deep but unrefreshing. The compound leaves behind a sense of having lost time rather than having spent it, as though you fell asleep in one place and woke up in another with no memory of the journey between.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(10)

Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
Physical disconnection— A perceptual distancing from one's own physical body that ranges from a subtle sense of numbness or ...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...

Tactile(1)

Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...

Cognitive & Perceptual Effects

Visual(9)

Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...

Pharmacology

MXP acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the “k-hole.”

Although it has not been formally studied, the feelings of physical and emotional euphoria which many users report suggests that it may also have action as a dopamine and / or a noradrenaline reuptake inhibitor.

It should be noted that like other diaryethylamines, methoxphenidine is reported to have a much more rapid onset and lower half-life when vaporized or smoked. When consumed this way, it is a suspected to be carcinogenic when excess heat is used. Some user reports have concluded that vaporization requires as low as 20% of what would be a common oral dose for that person.

The toxicity and long-exact toxic dosage is unknown. This is because MXP has very little history of human usage.

Anecdotal reports from those who have tried this substance that there do not seem to be any negative health effects attributed to simply trying it by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

As with other NMDA receptor antagonists,moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with Cross-all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.

Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
China:** As of October 2015, methoxphenidine is a controlled substance in China.
Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Italy:** Methoxphenidine is a prohibited substance in Italy.
Sweden:** Methoxphenidine is a prohibited substance in Sweden.
Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Methoxphenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Methoxphenidine is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Methoxphenidine is not currently scheduled in the United States. This means it is not specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Responsible use
Research chemical
Dissociative
Diarylethylamine
Diphenidine
Ephenidine
MXP (Wikipedia)
MXP (Erowid Vault)
MXP (Isomer Design)
Discussion
The Big & Dandy Methoxphenidine / MXP / 2-MeO-Diphenidine Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

=References=

Interactions

Substance	Status	Note
Desomorphine	Dangerous	Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Dissociatives	Dangerous	—
Naloxone	Dangerous	Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
3-Cl-PCP	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
3-HO-PCE	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
3-HO-PCP	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
3-MeO-PCE	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
3-MeO-PCMo	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
3-MeO-PCP	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
4-MeO-PCP	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Anandamide	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
APICA	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Cake	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Cannabidiol	Caution	Cannabis can intensify dissociation and increase confusion and disorientation
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Deschloroetizolam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Deschloroketamine	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Diclazepam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Diphenidine	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Ephenidine	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Eszopiclone	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Etizolam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Flubromazepam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Flubromazolam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Flunitrazepam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Flunitrazolam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Gaboxadol	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
HXE	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Inhalants	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Lorazepam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Memantine	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Mephenaqualone	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Metizolam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Midazolam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
MXiPr	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Nicotine	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Nifoxipam	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
O-PCE	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
PCE	Caution	Compounding dissociative effects can cause confusion, mania, and loss of motor control
Pentobarbital	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
Phenobarbital	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
SAMe	Caution	Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression
1,3-Butanediol	Low Risk & Synergy	Produces unique synergistic effects; often combined
25E-NBOH	Low Risk & Synergy	Produces unique synergistic effects; often combined
2C-T	Low Risk & Synergy	Produces unique synergistic effects; often combined
2C-T-2	Low Risk & Synergy	Produces unique synergistic effects; often combined
2C-T-21	Low Risk & Synergy	Produces unique synergistic effects; often combined
2C-T-7	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ayahuasca	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Produces unique synergistic effects; often combined
DOM	Low Risk & Synergy	Produces unique synergistic effects; often combined
DPT	Low Risk & Synergy	Produces unique synergistic effects; often combined
Efavirenz	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Produces unique synergistic effects; often combined
Methallylescaline	Low Risk & Synergy	Produces unique synergistic effects; often combined
MiPT	Low Risk & Synergy	Produces unique synergistic effects; often combined
MPT	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Produces unique synergistic effects; often combined

History

Methoxphenidine is an example of a designer drug, specifically chosen to mimic the functional or structural features of commonly used illicit substances and circumvent government regulation.

Methoxphenidine, or 2-MeO-Diphenidine, is a synthetic compound of the diarylethylamine class. Methoxphenidine's chemical structure contains a substituted phenethylamine skeleton with an additional phenyl ring bound to Rα. The terminal amino group of the phenethylamine chain is incorporated into a piperidine ring. Hence, methoxphenidine belongs to the piperidine dissociative class of compounds.

Methoxphenidine is a structural analog of diphenidine, featuring a methoxy group at the two position of a phenyl group.

The toxicity and long-exact toxic dosage is unknown. This is because MXP has very little history of human usage.

It is strongly recommended that one use harm reduction practices when using this substance.

Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
China:** As of October 2015, methoxphenidine is a controlled substance in China.
Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Italy:** Methoxphenidine is a prohibited substance in Italy.
Sweden:** Methoxphenidine is a prohibited substance in Sweden.
Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Methoxphenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Methoxphenidine is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Methoxphenidine is not currently scheduled in the United States. This means it is not specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Responsible use
Research chemical
Dissociative
Diarylethylamine
Diphenidine
Ephenidine
MXP (Wikipedia)
MXP (Erowid Vault)
MXP (Isomer Design)
Discussion
The Big & Dandy Methoxphenidine / MXP / 2-MeO-Diphenidine Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

=References=

Toxicity & Safety

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens The toxicity and long-term health effects of recreational MXP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MXP has very little history of human usage.

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

As with other NMDA receptor antagonists, the chronic use of MXP can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of MXP develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MXP presents cross-tolerance with all dissociatives, meaning that after the consumption of MXP all dissociatives will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Depressants (e.g. 2M2B, alcohol, barbiturates, benzodiazepines, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another and at higher doses, can lead to a sudden, unexpected loss of consciousness along with dangerously depressed respiration. There is also an increased risk of vomiting while unconsciousness and dying from the resulting suffocation. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Stimulants (e.g. amphetamine, cocaine, methylphenidate, MDMA) - This combination can potentiate the anxiety-inducing, manic, delusional and disinhibiting effects of dissociatives, particularly those without pronounced motor suppressing components such as ketamine. The sum of these effects can increase the likelihood of an anxiety attack, delusions or a psychotic episode. There is also evidence that suggests that combining these two increases their neurotoxicity. Anecdotally, worsened comedowns are also commonly reported when these two classes of substances are combined.
Dissociatives (e.g. dextromethorphan, ketamine, methoxetamine, PCP) - Combination can unpredictably potentiate amnesia, sedation, motor control loss and delusions. It may also result in a sudden loss of consciousness along with a dangerous amount of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.

Addiction Potential

moderately addictive with a high potential for abuse

Overdose Information

Overdose on Methoxphenidine can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.

Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.Critical dangers:

Respiratory depression: Particularly when combined with other depressants
Aspiration: Loss of protective reflexes combined with nausea creates choking risk
Hyperthermia or hypothermia: Impaired thermoregulation at high dosesEmergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.

Legal Status

Canada:** As of March 2016, MT-45 and its analogues, one of which is methoxphenidine, are schedule I controlled substances. Possession without legal authority can result in maximum 7 years imprisonment. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the substance.
China:** As of October 2015, methoxphenidine is a controlled substance in China.
Germany:** Methoxphenidine is a controlled substance under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Italy:** Methoxphenidine is a prohibited substance in Italy.
Sweden:** Methoxphenidine is a prohibited substance in Sweden.
Switzerland:** Methoxphenidine is a controlled substance specifically named under Verzeichnis E.
Turkey:** Methoxphenidine is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Methoxphenidine is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Methoxphenidine is not currently scheduled in the United States. This means it is not specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
Responsible use
Research chemical
Dissociative
Diarylethylamine
Diphenidine
Ephenidine
MXP (Wikipedia)
MXP (Erowid Vault)
MXP (Isomer Design)
Discussion
The Big & Dandy Methoxphenidine / MXP / 2-MeO-Diphenidine Thread (Bluelight)
Wallach, J., Kang, H., Colestock, T., Morris, H., Bortolotto, Z. A., Collingridge, G. L., ... & Adejare, A. (2016). Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One, 11(6), e0157021. https://doi.org/10.1371/journal.pone.0157021
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620

=References=

Methoxphenidine

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(10)

Tactile(1)

Cognitive & Perceptual Effects

Visual(9)

Pharmacology

Detection Methods

Standard Drug Panel Inclusion

Urine Detection

Blood and Serum Detection

Hair Follicle Detection

Confirmatory Methods

Reagent Testing

Interactions

History

Harm Reduction

Toxicity & Safety

Addiction Potential

Overdose Information

Dangerous Interactions

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (8)

Community Discussions (1)

See Also

References (5)

Frequently Asked Questions

Cognitive(15)

Auditory(1)

Transpersonal(1)

Full	develops with prolonged and repeated use
Half	3 - 7 days
Zero	1 - 2 weeks